Cargando…

Increased expression of complement components in tuberous sclerosis complex and focal cortical dysplasia type 2B brain lesions

OBJECTIVE: Increasing evidence supports the contribution of inflammatory mechanisms to the neurological manifestations of epileptogenic developmental pathologies linked to mammalian target of rapamycin (mTOR) pathway dysregulation (mTORopathies), such as tuberous sclerosis complex (TSC) and focal co...

Descripción completa

Detalles Bibliográficos
Autores principales: Gruber, Victoria‐Elisabeth, Luinenburg, Mark J., Colleselli, Katrin, Endmayr, Verena, Anink, Jasper J., Zimmer, Till S., Jansen, Floor, Gosselaar, Peter, Coras, Roland, Scholl, Theresa, Blumcke, Ingmar, Pimentel, José, Hainfellner, Johannes A., Höftberger, Romana, Rössler, Karl, Feucht, Martha, van Scheppingen, Jackelien, Aronica, Eleonora, Mühlebner, Angelika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299842/
https://www.ncbi.nlm.nih.gov/pubmed/34904712
http://dx.doi.org/10.1111/epi.17139
_version_ 1784751070381080576
author Gruber, Victoria‐Elisabeth
Luinenburg, Mark J.
Colleselli, Katrin
Endmayr, Verena
Anink, Jasper J.
Zimmer, Till S.
Jansen, Floor
Gosselaar, Peter
Coras, Roland
Scholl, Theresa
Blumcke, Ingmar
Pimentel, José
Hainfellner, Johannes A.
Höftberger, Romana
Rössler, Karl
Feucht, Martha
van Scheppingen, Jackelien
Aronica, Eleonora
Mühlebner, Angelika
author_facet Gruber, Victoria‐Elisabeth
Luinenburg, Mark J.
Colleselli, Katrin
Endmayr, Verena
Anink, Jasper J.
Zimmer, Till S.
Jansen, Floor
Gosselaar, Peter
Coras, Roland
Scholl, Theresa
Blumcke, Ingmar
Pimentel, José
Hainfellner, Johannes A.
Höftberger, Romana
Rössler, Karl
Feucht, Martha
van Scheppingen, Jackelien
Aronica, Eleonora
Mühlebner, Angelika
author_sort Gruber, Victoria‐Elisabeth
collection PubMed
description OBJECTIVE: Increasing evidence supports the contribution of inflammatory mechanisms to the neurological manifestations of epileptogenic developmental pathologies linked to mammalian target of rapamycin (mTOR) pathway dysregulation (mTORopathies), such as tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD). In this study, we aimed to investigate the expression pattern and cellular distribution of the complement factors C1q and C3 in resected cortical tissue of clinically well‐characterized patients with TSC and FCD2B. METHODS: We applied immunohistochemistry in TSC (n = 29) and FCD2B (n = 32) samples and compared them to autopsy and biopsy controls (n = 27). Furthermore, protein expression was observed via Western blot, and for descriptive colocalization studies immunofluorescence double labeling was performed. RESULTS: Protein expression for C3 was significantly upregulated in TSC and FCD2B white and gray matter lesions compared to controls. Staining of the synaptic vesicle protein synaptophysin showed a remarkable increase in the white matter of both TSC and FCD2B. Furthermore, confocal imaging revealed colocalization of complement factors with astroglial, microglial, neuronal, and abnormal cells in various patterns. SIGNIFICANCE: Our results demonstrate that the prominent activation of the complement pathway represents a common pathological hallmark of TSC and FCD2B, suggesting that complement overactivation may play a role in these mTORopathies.
format Online
Article
Text
id pubmed-9299842
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92998422022-07-21 Increased expression of complement components in tuberous sclerosis complex and focal cortical dysplasia type 2B brain lesions Gruber, Victoria‐Elisabeth Luinenburg, Mark J. Colleselli, Katrin Endmayr, Verena Anink, Jasper J. Zimmer, Till S. Jansen, Floor Gosselaar, Peter Coras, Roland Scholl, Theresa Blumcke, Ingmar Pimentel, José Hainfellner, Johannes A. Höftberger, Romana Rössler, Karl Feucht, Martha van Scheppingen, Jackelien Aronica, Eleonora Mühlebner, Angelika Epilepsia Research Article OBJECTIVE: Increasing evidence supports the contribution of inflammatory mechanisms to the neurological manifestations of epileptogenic developmental pathologies linked to mammalian target of rapamycin (mTOR) pathway dysregulation (mTORopathies), such as tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD). In this study, we aimed to investigate the expression pattern and cellular distribution of the complement factors C1q and C3 in resected cortical tissue of clinically well‐characterized patients with TSC and FCD2B. METHODS: We applied immunohistochemistry in TSC (n = 29) and FCD2B (n = 32) samples and compared them to autopsy and biopsy controls (n = 27). Furthermore, protein expression was observed via Western blot, and for descriptive colocalization studies immunofluorescence double labeling was performed. RESULTS: Protein expression for C3 was significantly upregulated in TSC and FCD2B white and gray matter lesions compared to controls. Staining of the synaptic vesicle protein synaptophysin showed a remarkable increase in the white matter of both TSC and FCD2B. Furthermore, confocal imaging revealed colocalization of complement factors with astroglial, microglial, neuronal, and abnormal cells in various patterns. SIGNIFICANCE: Our results demonstrate that the prominent activation of the complement pathway represents a common pathological hallmark of TSC and FCD2B, suggesting that complement overactivation may play a role in these mTORopathies. John Wiley and Sons Inc. 2021-12-14 2022-02 /pmc/articles/PMC9299842/ /pubmed/34904712 http://dx.doi.org/10.1111/epi.17139 Text en © 2021 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research Article
Gruber, Victoria‐Elisabeth
Luinenburg, Mark J.
Colleselli, Katrin
Endmayr, Verena
Anink, Jasper J.
Zimmer, Till S.
Jansen, Floor
Gosselaar, Peter
Coras, Roland
Scholl, Theresa
Blumcke, Ingmar
Pimentel, José
Hainfellner, Johannes A.
Höftberger, Romana
Rössler, Karl
Feucht, Martha
van Scheppingen, Jackelien
Aronica, Eleonora
Mühlebner, Angelika
Increased expression of complement components in tuberous sclerosis complex and focal cortical dysplasia type 2B brain lesions
title Increased expression of complement components in tuberous sclerosis complex and focal cortical dysplasia type 2B brain lesions
title_full Increased expression of complement components in tuberous sclerosis complex and focal cortical dysplasia type 2B brain lesions
title_fullStr Increased expression of complement components in tuberous sclerosis complex and focal cortical dysplasia type 2B brain lesions
title_full_unstemmed Increased expression of complement components in tuberous sclerosis complex and focal cortical dysplasia type 2B brain lesions
title_short Increased expression of complement components in tuberous sclerosis complex and focal cortical dysplasia type 2B brain lesions
title_sort increased expression of complement components in tuberous sclerosis complex and focal cortical dysplasia type 2b brain lesions
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299842/
https://www.ncbi.nlm.nih.gov/pubmed/34904712
http://dx.doi.org/10.1111/epi.17139
work_keys_str_mv AT grubervictoriaelisabeth increasedexpressionofcomplementcomponentsintuberoussclerosiscomplexandfocalcorticaldysplasiatype2bbrainlesions
AT luinenburgmarkj increasedexpressionofcomplementcomponentsintuberoussclerosiscomplexandfocalcorticaldysplasiatype2bbrainlesions
AT collesellikatrin increasedexpressionofcomplementcomponentsintuberoussclerosiscomplexandfocalcorticaldysplasiatype2bbrainlesions
AT endmayrverena increasedexpressionofcomplementcomponentsintuberoussclerosiscomplexandfocalcorticaldysplasiatype2bbrainlesions
AT aninkjasperj increasedexpressionofcomplementcomponentsintuberoussclerosiscomplexandfocalcorticaldysplasiatype2bbrainlesions
AT zimmertills increasedexpressionofcomplementcomponentsintuberoussclerosiscomplexandfocalcorticaldysplasiatype2bbrainlesions
AT jansenfloor increasedexpressionofcomplementcomponentsintuberoussclerosiscomplexandfocalcorticaldysplasiatype2bbrainlesions
AT gosselaarpeter increasedexpressionofcomplementcomponentsintuberoussclerosiscomplexandfocalcorticaldysplasiatype2bbrainlesions
AT corasroland increasedexpressionofcomplementcomponentsintuberoussclerosiscomplexandfocalcorticaldysplasiatype2bbrainlesions
AT scholltheresa increasedexpressionofcomplementcomponentsintuberoussclerosiscomplexandfocalcorticaldysplasiatype2bbrainlesions
AT blumckeingmar increasedexpressionofcomplementcomponentsintuberoussclerosiscomplexandfocalcorticaldysplasiatype2bbrainlesions
AT pimenteljose increasedexpressionofcomplementcomponentsintuberoussclerosiscomplexandfocalcorticaldysplasiatype2bbrainlesions
AT hainfellnerjohannesa increasedexpressionofcomplementcomponentsintuberoussclerosiscomplexandfocalcorticaldysplasiatype2bbrainlesions
AT hoftbergerromana increasedexpressionofcomplementcomponentsintuberoussclerosiscomplexandfocalcorticaldysplasiatype2bbrainlesions
AT rosslerkarl increasedexpressionofcomplementcomponentsintuberoussclerosiscomplexandfocalcorticaldysplasiatype2bbrainlesions
AT feuchtmartha increasedexpressionofcomplementcomponentsintuberoussclerosiscomplexandfocalcorticaldysplasiatype2bbrainlesions
AT vanscheppingenjackelien increasedexpressionofcomplementcomponentsintuberoussclerosiscomplexandfocalcorticaldysplasiatype2bbrainlesions
AT aronicaeleonora increasedexpressionofcomplementcomponentsintuberoussclerosiscomplexandfocalcorticaldysplasiatype2bbrainlesions
AT muhlebnerangelika increasedexpressionofcomplementcomponentsintuberoussclerosiscomplexandfocalcorticaldysplasiatype2bbrainlesions